Pharmaceutical maker Eli Lilly and Company has purchased Disarm Therapeutics, a startup biotechnology firm founded by researchers at Washington University
New discovery could help improve cancer vaccines
Cancer vaccines have shown promise in treating certain tumors, such as melanoma. But such vaccines have limitations. They often target
Basis of developmental disabilities focus of $11.3 million in grants
Researchers at Washington University School of Medicine in St. Louis have received a pair of grants totaling $11.3 million to
idecabtagene vicleucel
idecabtagene vicleucel U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for
